Abstract
Serum calcitonin (CT) has important diagnostic and prognostic value in patients with medullary thyroid carcinoma (MTC). Although CT can be routinely quantified by a variety of 2-site immunoassays, different assays may yield very different results. This variability, particularly at low CT concentrations, led to the recommendation to use reliable and sensitive assays in the screening of MTC and C-cell hyperplasia (1). To highlight CT variability at high concentrations, we measured 43 serum samples by use of a polyclonal IRMA and by a monoclonal IRMA. The single-step polyclonal assay used 2 different goat antibodies (as the capture and labeled antibodies), which were specific for well-defined regions of the CT molecule, with no cross-reactivity with parathyroid hormone, thyroid-stimulating hormone, CT gene–related peptide, porcine CT, or salmon CT. The reagent set was used according to the manufacturer’s instructions (Calcitonin Assay, Scantibodies Laboratory, Inc.). The …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
